Pages Menu
FacebookTwitterPinterestRss
Categories Menu

Posted by on Apr 30, 2018 in Foundation NewsLine, Type C |

CTD Holdings Press Release

PRESS RELEASE FROM CTD HOLDINGS

CTD Holdings:  FDA Authorizes CTD to Proceed with Extension Protocol to US Phase I Trappsol® Cyclo™ Trial for Niemann-Pick Disease Type C.

CLICK HERE for the complete announcement.

Share this!

Please spread the word!

FACEBOOK
TWITTER
PINTEREST